Table 3.
Prediction accuracy of the serum VCA-/EBNA1-IgA antibody tests and the models combining serum EBV antibody levels and the comprehensive risk score with different cutoff values in the combined dataset.
| Model | Cut off | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|
| VCA-/EBNA1-IgA | P ≥ 0.98 | 80.13% | 97.39% | 4.70% | 99.97% |
| CRS (Top 40 percentile) + VCA-/EBNA1-IgA | CRS ≥ 3.23 and P ≥ 0.98 | 62.95% | 99.48% | 16.22% | 99.94% |
| CRS (Top 30 percentile) + VCA-/EBNA1-IgA | CRS ≥ 3.62 and P ≥ 0.98 | 53.21% | 99.83% | 32.93% | 99.92% |
| CRS (Top 20 percentile) + VCA-/EBNA1-IgA | CRS ≥ 3.88 and P ≥ 0.98 | 41.28% | 99.91% | 43.24% | 99.91% |
| CRS (Top 10 percentile) + VCA-/EBNA1-IgA | CRS ≥ 4.30 and P ≥ 0.98 | 25.64% | 99.91% | 32.12% | 99.88% |
CRS comprehensive risk score, AUC area under the curve, CI confidence interval, PPV positive predictive value, NPV negative predictive value.